Seminars in Radiation Oncology
Volume 19, Issue 1 , Pages 63-68 , January 2009

Molecular Target Approaches in Head and Neck Cancer: Epidermal Growth Factor Receptor and Beyond

  • Paul M. Harari, MD

      Affiliations

    • Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI
    • Corresponding Author InformationAddress reprint requests to Paul M. Harari, MD, Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, 600 Highland Ave, K4/336 CSC, Madison, WI 53792
    • ,
  • Deric L. Wheeler, PhD

      Affiliations

    • University of Wisconsin School of Medicine and Public Health, Department of Human Oncology, Madison, WI
    • ,
  • Jennifer R. Grandis, MD

      Affiliations

    • University of Pittsburgh School of Medicine, Pittsburgh, PA

References 

  1. Grandis JR, Chakraborty A, Zeng Q. Downmodulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. J Cell Biochem. 1998;69:55–62
  2. Grandis JR, Chakraborty A, Melhem MF. Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. Oncogene. 1997;15:409–416
  3. Grandis JR, Tweardy DJ, Melhem MF. Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma. Clin Cancer Res. 1998;4:13–20
  4. Grandis JR, Sok JC. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther. 2004;102:37–46
  5. Egloff AM, Grandis J. Epidermal growth factor receptor–targeted molecular therapeutics for head and neck squamous cell carcinoma. Expert Opin Ther Targets. 2006;10:639–647
  6. Grandis JR, Melhem MF, Gooding WE. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 1998;90:824–832
  7. Ang KK, Berkey BA, Tu X. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002;62:7350–7356
  8. Chung CH, Ely K, McGavran L. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol. 2006;24:4170–4176
  9. Grandis JR, Zeng Q, Tweardy DJ. Retinoic acid normalizes the increased gene transcription rate of TGF-alpha and EGFR in head and neck cancer cell lines. Nat Med. 1996;2:237–240
  10. Rubin Grandis J, Tweardy DJ, Melhem MF. Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma. Clin Cancer Res. 1998;4:13–20
  11. Lui VW, Grandis JR. EGFR-mediated cell cycle regulation. Anticancer Res. 2002;22:1–11
  12. Thomas SM, Grandis JR. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat Rev. 2004;30:255–268
  13. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999;59:1935–1940
  14. Burtness B, Goldwasser MA, Flood W. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol. 2005;23:8646–8654
  15. Bonner JA, Harari PM, Giralt J. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–578
  16. Soulieres D, Senzer NN, Vokes EE. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004;22:77–85
  17. Agulnik M, Cohen EW, Cohen RB. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol. 2007;25:3978–3984
  18. Siegfried JM, Krishnamachary N, Gaither Davis A. Evidence for autocrine actions of neuromedin B and gastrin-releasing peptide in non-small cell lung cancer. Pulm Pharmacol Ther. 1999;12:291–302
  19. Gallo O, Franchi A, Magnelli L. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer (Implications for tumor angiogenesis and metastasis). Neoplasia. 2001;3:53–61
  20. Masferrer JL, Leahy KM, Koki AT. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000;60:1306–1311
  21. Gschwind A, Prenzel N, Ullrich A. Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation. Cancer Res. 2002;62:6329–6336
  22. Klingmuller U, Wu H, Hsiao JG. Identification of a novel pathway important for proliferation and differentiation of primary erythroid progenitors. Proc Natl Acad Sci U S A. 1997;94:3016–3021
  23. Altorki NK, Keresztes RS, Port JL. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol. 2003;21:2645–2650
  24. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol. 2006;24:2666–2672
  25. Temam S, Kawaguchi H, El-Naggar AK. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol. 2007;25:2164–2170
  26. Sugawa N, Ekstrand AJ, James CD. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci U S A. 1990;87:8602–8606
  27. Ekstrand AJ, James CD, Cavenee WK. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res. 1991;51:2164–2172
  28. Huang HS, Nagane M, Klingbeil CK. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem. 1997;272:2927–2935
  29. Moscatello DK, Montgomery RB, Sundareshan P. Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene. 1996;13:85–96
  30. Scaltriti M, Rojo F, Ocana A. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst. 2007;99:628–638
  31. Sok JC, Coppelli FM, Thomas SM. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res. 2006;12:5064–5073
  32. Mellinghoff IK, Wang MY, Vivanco I. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005;353:2012–2024
  33. Friedman HS, Bigner DD. Glioblastoma multiforme and the epidermal growth factor receptor. N Engl J Med. 2005;353:1997–1999
  34. Learn CA, Hartzell TL, Wikstrand CJ. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res. 2004;10:3216–3224
  35. Mizoguchi M, Betensky RA, Batchelor TT. Activation of STAT3 (MAPK, and AKT in malignant astrocytic gliomas: Correlation with EGFR status, tumor grade, and survival). J Neuropathol Exp Neurol. 2006;65:1181–1188
  36. Johns TG, Perera RM, Vernes SC. The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization. Clin Cancer Res. 2007;13:1911–1925
  37. Li B, Yuan M, Kim IA. Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/Akt pathway and promotes radioresistance in cells of astrocytic origin. Oncogene. 2004;23:4594–4602
  38. Kuan CT, Wikstrand CJ, Archer G. Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv. Int J Cancer. 2000;88:962–969
  39. Scott AM, Lee FT, Tebbutt N. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci U S A. 2007;104:4071–4076
  40. Ji H, Zhao X, Yuza Y. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci U S A. 2006;103:7817–7822
  41. Reid A, Vidal L, Shaw H. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer. 2007;43:481–489
  42. Sequist LV, Bell DW, Lynch TJ. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol. 2007;25:587–595
  43. Riely GJ, Politi KA, Miller VA. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res. 2006;12:7232–7241
  44. Arteaga CL, Baselga J. Tyrosine kinase inhibitors: Why does the current process of clinical development not apply to them?. Cancer Cell. 2004;5:525–531
  45. Engelman JA, Zejnullahu K, Mitsudomi T. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039–1043
  46. Peruzzi B, Bottaro DP. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res. 2006;12:3657–3660
  47. Jo M, Stolz DB, Esplen JE. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem. 2000;275:8806–8811
  48. Mendelsohn J. Antibody-mediated EGF receptor blockade as an anticancer therapy: From the laboratory to the clinic. Cancer Immunol Immunother. 2003;52:342–346
  49. Sunada H, Magun BE, Mendelsohn J. Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc Natl Acad Sci U S A. 1986;83:3825–3829
  50. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol. 2005;23:2445–2459
  51. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol. 2006;33:369–385
  52. Bonner JA, Harari PM, Giralt J. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–578
  53. Cunningham D, Humblet Y, Siena S. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–345
  54. Van Cutsem E, Peeters M, Siena S. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25:1658–1664
  55. Mukohara T, Engelman JA, Hanna NH. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst. 2005;97:1185–1194
  56. Ciardiello F, Bianco R, Caputo R. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res. 2004;10:784–793
  57. Viloria-Petit A, Crombet T, Jothy S. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis. Cancer Res. 2001;61:5090–5101
  58. Wheeler DL, Huang S, Kruser TJ. Mechanisms of acquired resistance to cetuximab: Role of HER (ErbB) family members. Oncogene. 2008;27:3944–3956
  59. Sergina NV, Rausch M, Wang D. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007;445:437–441
  60. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18:1926–1945
  61. Allen GW, Saba C, Armstrong EA. Insulin-like growth factor-I receptor signaling blockade combined with radiation. Cancer Res. 2007;67:1155–1162
  62. Reiter R, Gais P, Jutting U. Aurora kinase A messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma. Clin Cancer Res. 2006;12:5136–5141

 PMH holds research and/or consulting agreements with Amgen, AstraZeneca, Cellectar, Genentech and ImClone.

PII: S1053-4296(08)00065-9

doi: 10.1016/j.semradonc.2008.09.009

Seminars in Radiation Oncology
Volume 19, Issue 1 , Pages 63-68 , January 2009

Article Tools

* Image Usage & Resolution